EA201171244A1 - Способы лечения видов рака антисмысловыми олигонуклеотидами her3 - Google Patents

Способы лечения видов рака антисмысловыми олигонуклеотидами her3

Info

Publication number
EA201171244A1
EA201171244A1 EA201171244A EA201171244A EA201171244A1 EA 201171244 A1 EA201171244 A1 EA 201171244A1 EA 201171244 A EA201171244 A EA 201171244A EA 201171244 A EA201171244 A EA 201171244A EA 201171244 A1 EA201171244 A1 EA 201171244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
treating cancer
her3
cancer types
sense oligonucleotides
Prior art date
Application number
EA201171244A
Other languages
English (en)
Inventor
Исянь Чжан
Чжэнсин Цюй
Ли Мартин Гринбергер
Original Assignee
Сантарис Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/С filed Critical Сантарис Фарма А/С
Publication of EA201171244A1 publication Critical patent/EA201171244A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Один аспект изобретения предоставляет способы лечения видов рака, которые устойчивы к лечению ингибитором белковых тирозинкиназ, путем совместной обработки ингибитором белковых тирозинкиназ и одним или несколькими антисмысловыми олигомерами, которые уменьшают экспрессию HER3, и/или HER2, и/или EGFR. Другой аспект изобретения предоставляет способы лечения видов рака путем совместной обработки ингибитором HER2 и одним или несколькими антисмысловыми олигомерами, которые уменьшают экспрессию HER3.
EA201171244A 2009-04-14 2010-04-14 Способы лечения видов рака антисмысловыми олигонуклеотидами her3 EA201171244A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16909309P 2009-04-14 2009-04-14
PCT/US2010/031005 WO2010120861A1 (en) 2009-04-14 2010-04-14 Methods of treating cancers with her3 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
EA201171244A1 true EA201171244A1 (ru) 2012-05-30

Family

ID=42272071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171244A EA201171244A1 (ru) 2009-04-14 2010-04-14 Способы лечения видов рака антисмысловыми олигонуклеотидами her3

Country Status (11)

Country Link
US (1) US20120076781A1 (ru)
EP (1) EP2419110A4 (ru)
JP (1) JP2012524096A (ru)
KR (1) KR20140014367A (ru)
CN (1) CN102395374A (ru)
AR (1) AR076053A1 (ru)
CA (1) CA2758005A1 (ru)
EA (1) EA201171244A1 (ru)
IL (1) IL215683A0 (ru)
TW (1) TW201036619A (ru)
WO (1) WO2010120861A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
WO2012068000A2 (en) * 2010-11-15 2012-05-24 Enzon Pharmaceuticals, Inc. Methods of treating cancers with her3 and pik3ca antisense oligonucleotides
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
WO2017184082A1 (en) * 2016-04-22 2017-10-26 Nanyang Technological University A lymphocyte permeating chimeric oligonucleotide, methods and uses thereof
WO2020080892A1 (ko) * 2018-10-19 2020-04-23 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100024410A (ko) * 2007-05-11 2010-03-05 엔즌 파마슈티칼스, 인코포레이티드 Ｈｅｒ３ 조절용 ｒｎａ 길항제 화합물

Also Published As

Publication number Publication date
TW201036619A (en) 2010-10-16
WO2010120861A1 (en) 2010-10-21
KR20140014367A (ko) 2014-02-06
EP2419110A4 (en) 2013-08-07
AR076053A1 (es) 2011-05-18
JP2012524096A (ja) 2012-10-11
CN102395374A (zh) 2012-03-28
US20120076781A1 (en) 2012-03-29
CA2758005A1 (en) 2010-10-21
IL215683A0 (en) 2012-01-31
EP2419110A1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
EA201171244A1 (ru) Способы лечения видов рака антисмысловыми олигонуклеотидами her3
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
NI201100012A (es) Antagonistas específicos del receptor fgf - r4.
CY1118157T1 (el) Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201792443A1 (ru) МОДУЛЯТОРЫ K-Ras
EA201591145A1 (ru) Ингибиторы гистондеметилазы
EA201201474A1 (ru) Способы лечения рака молочной железы
BRPI0908127A2 (pt) Método para o tratamento do câncer da próstata com degarelix antagonista do gnrh
EA201170831A1 (ru) Аминопиразольное соединение
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201070595A1 (ru) Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
EA201591509A1 (ru) Ингибиторы cdc7
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
EA201170660A1 (ru) Избирательная для erbb-3 (her3) комбинированная терапия
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
BR112012003653A2 (pt) "método de tratar o câncer."